Compounds > 1-(5-isoquinolinesulfonyl)-2-methylpiperazine

1-(5-isoquinolinesulfonyl)-2-methylpiperazine and 1,2-dipalmitoylphosphatidylcholine

1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with 1,2-dipalmitoylphosphatidylcholine in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Chander, A; Dodia, C; Fisher, AB1
Ahsan, F; Gupta, N; Gupta, V; Komatsu, M; McMurtry, IF; Mehvar, R; Nozik-Grayck, E; Oka, M; Shaik, IH1
Asai, T; Fukuta, T; Honda, M; Namba, M; Oku, N; Yamamoto, H; Yanagida, M; Yanagida, Y1

Other Studies

3 other study(ies) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and 1,2-dipalmitoylphosphatidylcholine

ArticleYear
Secretagogues for lung surfactant increase lung uptake of alveolar phospholipids.
    The American journal of physiology, 1989, Volume: 257, Issue:4 Pt 1

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1,2-Dipalmitoylphosphatidylcholine; Animals; In Vitro Techniques; Isoquinolines; Kinetics; Lung; Male; Piperazines; Protein Kinase Inhibitors; Pulmonary Alveoli; Pulmonary Surfactants; Rats; Rats, Inbred Strains; Terbutaline; Tetradecanoylphorbol Acetate

1989
Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.
    Journal of controlled release : official journal of the Controlled Release Society, 2013, Apr-28, Volume: 167, Issue:2

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1,2-Dipalmitoylphosphatidylcholine; Aerosols; Alkaline Phosphatase; Animals; Bronchoalveolar Lavage Fluid; Cell Line; Cell Survival; Cholesterol; Drug Stability; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; L-Lactate Dehydrogenase; Liposomes; Macrophages, Alveolar; Male; Myocytes, Smooth Muscle; Protein Kinase Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Vasodilation; Vasodilator Agents

2013
Release rate is a key variable affecting the therapeutic effectiveness of liposomal fasudil for the treatment of cerebral ischemia/reperfusion injury.
    Biochemical and biophysical research communications, 2020, 10-22, Volume: 531, Issue:4

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1,2-Dipalmitoylphosphatidylcholine; Ammonium Sulfate; Animals; Brain; Citric Acid; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Liberation; Liposomes; Male; Phosphatidylcholines; Quaternary Ammonium Compounds; Rats, Wistar; Reperfusion Injury; Treatment Outcome

2020